Polyrizon Ltd. has submitted amended claims to expand the scope of its U.S. patent application for its intranasal drug delivery platform. The expanded claims now cover not only the core mucoadhesive composition but also drug delivery systems and methods designed to improve drug effectiveness by increasing residence time and mucosal contact. This move strengthens Polyrizon's global intellectual property portfolio and enhances the potential applicability of its technology across various therapeutic areas. The platform aims to improve drug absorption and efficacy through prolonged retention and controlled film formation on mucosal surfaces.
STARLUX Airlines has introduced the AIRSORAYAMA Silver, the world's largest flying canvas, featuring a unique liquid-metal livery designed by Japanese artist Hajime Sorayama. The aircraft, an Airbus A350-1000, was unveiled in Toulouse and will be pil...
Intertape Polymer Corp (IPG) has introduced a new PCR Air Pillow Film made with 50% recycled materials, including 35% post-consumer recycled content. This high-performance packaging film is designed to help companies meet sustainability goals without...
The global infant heart monitor market, valued at $2.83 billion in 2025, is projected to grow to $7.93 billion by 2035 at a CAGR of 10.85%. Growth is fueled by advances in wearable and wireless monitoring technologies, increased adoption of home care...
TransDigm Group (TDG) has been upgraded to a Strong Buy rating with a 39% increase in its price target to $1,860.41. The company benefits from its proprietary aerospace components that generate high-margin, recurring aftermarket revenue, supported by...
Kirby McInerney LLP has launched an investigation into MercadoLibre following the company's May 2026 disclosure that the average loan term in Brazil extended from 5 to 8 months, prompting provisions. This announcement caused MercadoLibre's stock to d...
